Accuray

Accuray is a U.S. medical technology company serving the radiation oncology market with treatment systems, software and related services. Its activities focus on applications including precision radiosurgery, stereotactic radiation therapy and image-guided radiation therapy, with systems generally installed in hospitals and specialist cancer centers. Its best-known product families include the CyberKnife radiosurgery system and the Radixact helical tomotherapy system, which is based on the TomoTherapy technology platform. The brand emphasizes precision targeting, treatment planning, image guidance and motion management. In addition to equipment, Accuray provides software, upgrades, maintenance, clinical support and training. Accuray Incorporated is publicly traded on Nasdaq and serves international markets. Product availability and configurations vary by country according to regulatory approvals and company disclosures.

Accuray grew out of the development of precision radiation-treatment technology in the 1990s and built its CyberKnife product family around image-guided robotic radiosurgery. The system uses imaging and dynamically directed radiation delivery to provide highly focused treatments. As radiation oncology increasingly adopted image guidance, stereotactic treatment and patient-motion management, Accuray broadened its activities into a wider range of radiation-therapy solutions. The company later expanded into the helical tomotherapy field through the development and integration of the TomoTherapy technology platform, leading to the Radixact product family. Its business subsequently extended beyond equipment sales to treatment-planning software, image guidance, system upgrades, maintenance and clinical support. Accuray now operates as Accuray Incorporated and is listed on Nasdaq. Product portfolios, indications and geographic availability depend on local medical-device approvals.

• 1990

  Origins of the Company

  [1]Accuray official company informationaccuray.com

  Accuray's business traces its origins to the development of precision radiation therapy technology in the 1990s.

• Entry into Helical Tomotherapy

  [3]Accuray Radixact product informationaccuray.com

  The company built around the TomoTherapy technology platform and developed the Radixact radiation therapy product line, expanding its product coverage in the radiation oncology market.

Precision radiosurgery, stereotactic radiotherapy, and image-guided radiotherapy solutions

• CyberKnife

  CyberKnife is Accuray's robotic radiosurgery product family. It combines image guidance with adjustable radiation delivery for highly precise, non-invasive radiation treatment of selected tumors or lesions. Indications and configurations vary by regulatory market.

• Radixact

  Radixact is Accuray's helical tomotherapy radiation therapy system, derived from the TomoTherapy technology platform. It supports image-guided treatment and complex target irradiation together with treatment-planning and imaging capabilities.

• TomoTherapy

  TomoTherapy is a radiation-therapy technology platform associated with Accuray's business. It is characterized by helical delivery and image guidance and forms the technological basis of the Radixact product family.

• 2021.08.11

  Reported2021.08.11

  Accuray CFO Shig Hamamatsu announces resignation[5]Accuray首席财务官Shig Hamamatsu宣布辞职prnewswire.com

  Accuray CFO Shig Hamamatsu announced his resignation to pursue an opportunity in another industry; he was to remain CFO through September 3, 2021, to help ensure a smooth transition.

• 2021.08.11

  Reported2021.08.11

  Accuray appoints Brandy Green interim CFO[5]Accuray首席财务官Shig Hamamatsu宣布辞职prnewswire.com

  Accuray announced the appointment of Vice President and Corporate Controller Brandy Green as interim CFO, effective September 4, 2021.

• 2021.06.22

  Reported2021.06.22

  Accuray announces Suzanne Winter's promotion to president[6]Accuray宣布Suzanne Winter晋升为总裁prnewswire.com

  Accuray announced that Suzanne Winter had been promoted to president, effective July 1, 2021. In the role, she will also oversee global manufacturing operations, the service organization, and quality and regulatory affairs.

• 2021.02.12

  Reported2021.02.19

  Accuray appoints Byron C. Scott to its board[7]Accuray任命Byron C. Scott为董事会成员prnewswire.com

  Accuray appointed Byron C. Scott to its Board of Directors, effective February 12, 2021.

• 2021.01.27

  Reported2021.01.27

  Accuray receives FDA clearance for ClearRT imaging[8]Accuray 的 ClearRT 成像系统获得 FDA 许可prnewswire.com

  Accuray reported that it received FDA 510(k) clearance for ClearRT Helical kVCT Imaging for the Radixact System.

• 2020.10.19

  Reported2020.10.19

  Accuray appoints Mike Leischer to lead the Americas region[9]Accuray任命Mike Leischer负责美洲地区prnewswire.com

  Accuray announced that it had appointed Mike Leischer as vice president and general manager of its Americas region, effective immediately. He will lead the region's commercial teams and its business strategy.

• 2020.06.26

  Reported2020.06.26

  Accuray launches CyberKnife S7 System[10]Accuray推出CyberKnife S7系统itnonline.com

  Accuray announced the launch of the CyberKnife S7 System, a radiation therapy device for stereotactic radiosurgery and stereotactic body radiation therapy.

• 2020.06.17

  Reported2020.06.17

  Accuray launches CyberKnife S7 System[11]Accuray推出CyberKnife S7系统prnewswire.com

  Accuray announced that it had launched the CyberKnife S7 System, a robotic radiation therapy device for treating tumors and neurologic disorders.

• 2020.01.28

  Reported2020.01.28

  Accuray updates fiscal 2020 adjusted EBITDA guidance[12]Accuray更新2020财年调整后EBITDA指引prnewswire.com

  Accuray reaffirmed its fiscal 2020 revenue guidance and raised its adjusted EBITDA guidance to a range of $21 million to $26 million, from the previous range of $19 million to $24 million.

• 2019.10.29

  Reported2019.10.29

  Accuray reports fiscal 2020 first-quarter results[13]Accuray公布2020财年第一季度业绩prnewswire.com

  Accuray reported its financial results for the first quarter of fiscal 2020, including revenue of $89.6 million and a net loss of $9.4 million.

Read more

1. 1Accuray official company informationaccuray.com
2. 2Accuray CyberKnife product informationaccuray.com
3. 3Accuray Radixact product informationaccuray.com
4. 4Accuray investor relationsinvestors.accuray.com
5. 5Accuray首席财务官Shig Hamamatsu宣布辞职prnewswire.com
6. 6Accuray宣布Suzanne Winter晋升为总裁prnewswire.com
7. 7Accuray任命Byron C. Scott为董事会成员prnewswire.com
8. 8Accuray 的 ClearRT 成像系统获得 FDA 许可prnewswire.com
9. 9Accuray任命Mike Leischer负责美洲地区prnewswire.com
10. 10Accuray推出CyberKnife S7系统itnonline.com
11. 11Accuray推出CyberKnife S7系统prnewswire.com
12. 12Accuray更新2020财年调整后EBITDA指引prnewswire.com
13. 13Accuray公布2020财年第一季度业绩prnewswire.com
14. 14Accuray Announces Preliminary First Quarter Fiscal 2022 Financial Results and Raises FY22 Revenue Guidance to range between $420 million to $427 millionprnewswire.com
15. 15Accuray Reports Fiscal 2022 First Quarter Financial Resultsprnewswire.com
16. 16Accuray Reports Fiscal 2022 Second Quarter Financial Resultsprnewswire.com
17. 17Accuray Reports Fiscal 2027 First Quarter Financial Resultsprnewswire.com
18. 18Accuray Reports Fourth Quarter and Fiscal 2020 Financial Resultsprnewswire.com